Health - Written Evidence [Back to Report]
Here you can browse the Written Evidence ordered by the House of Commons to be printed 22 March 2005.
CONTENTS
APPENDIX 1
Supplementary memorandum by Rethink Severe
Mental Illness (PI 2A)
APPENDIX 2
Memorandum by the Pharmaceutical Services
Negotiating Committee (PI 3)
APPENDIX 3
APPENDIX 4
Memorandum by CancerBACUP (PI 7)
APPENDIX 5
Memorandum by the American Pharmaceutical
Group (PI 13)
APPENDIX 6
Memorandum by the Prescription Medicines Code
of Practice Authority (PI 14)
APPENDIX 7
Memorandum by the Association of Information
Officers in the Pharmaceutical Industry (PI 15)
Annex
APPENDIX 8
Memorandum by EMG European Medicines Group
(PI 17)
APPENDIX 9
Memorandum by Novartis (PI 20)
APPENDIX 10
Memorandum by Cephalon UK Limited (PI 23)
APPENDIX 11
Memorandum by Critical Psychiatry Network
(PI 31)
APPENDIX 12
Memorandum by the Category Manager, Boots
the Chemists (PI 34)
APPENDIX 13
Memorandum by Long-term Medical Conditions
Alliance (PI 36)
APPENDIX 14
Memorandum of the Alzheimer's Society (PI
41)
Annex 1
APPENDIX 15
Memorandum by the General Medical Council
(PI 43)
APPENDIX 16
Memorandum by PharmacyHealthLink (PI 44)
APPENDIX 17
Memorandum by the Scottish Association for
Mental Health (PI 46)
APPENDIX 18
Memorandum by Professor Les Toop and Dr Dee
Richards (PI 49)
APPENDIX 19
Memorandum by Dr Peter R Mansefield on behalf
of Healthy Skepticism Inc (PI 50)
APPENDIX 20
Memorandum submitted by the Joint Task Force
on Medicines Partnership (PI 58)
APPENDIX 21
Memorandum by APRIL (Adverse Psychiatric Reactions
Information Link) (PI 60)
APPENDIX 22
Memorandum from the King's Fund (PI 81)
APPENDIX 23
Memorandum by The Wellcome Trust (PI 93)
APPENDIX 24
Memorandum by the Proprietary Association
of Great Britain (PI 94)
Annex 1
APPENDIX 25
Memorandum by Ray Moynihan (PI 98)
APPENDIX 26
Memorandum by Mel Read (PI 100)
APPENDIX 27
Memorandum by Nuffield Council on Bioethics
(PI 102)
Annex
APPENDIX 28
Supplementary evidence by the Association
of the British Pharmaceutical Industry (PI 35A)
APPENDIX 29
Letter from David Dickinson, to the Clerk
of the Committee (PI 127)
APPENDIX 30
Letter from the President, Faculty of Pharmaceutical
Medicine to the Chairman of the Committee (PI 120)
APPENDIX 31
Memorandum by the Medicines Commission (PI
112)
APPENDIX 32
Memorandum by Dr Julian Colledge (PI 113)
APPENDIX 33 (PI 125)
Memorandum by the University of Stirling
APPENDIX 34
Memorandum by the Association of the British
Pharmaceutical Industry in response to the Institute for Social
Marketing's Analysis of the Pharmaceutical Industry's Marketing
Documents (PI 126)
APPENDIX 35
Memorandum by the Prescription Medicines Code
of Practice Authority (PI 128)
APPENDIX 36
Memorandum by Lilly (PI 129)
APPENDIX 37
Supplementary memorandum by Pfizer Ltd (PI
130)
APPENDIX 38
Letter from AstraZeneca to the Clerk of the
Committee (PI 131)
APPENDIX 39
Supplementary memorandum by GlaxoSmithKline
(PI 132)
APPENDIX 40
Letter from the Corporate Affairs Director,
Wyeth Phamaceuticals, to the Clerk of the Committee (PI 133)
APPENDIX 41
Memorandum by the Chief Executive of the National
Pharmaceutical Association (PI 116)
APPENDIX 42
Memorandum by The Association for Human Pharmacology
in the Pharmaceutical Industry (PI 107)
APPENDIX 43
Letter from Malcolm Boyce to the Clerk of
the Committee (PI 107A)
APPENDIX 44
Memorandum by Pfizer (PI 28)
Annex (PI 28A)
APPENDIX 45
Memorandum by the British Association of Pharmaceutical
Wholesalers (PI 24)
APPENDIX 46
Supplementary memorandum by British Association
of Pharmaceutical Wholesalers (PI 24A)
APPENDIX 47
Letter from the Chairman, Medicines and Healthcare
Products Regulatory Agency to the Clerk of the Committee (PI 124A)
Annex C
APPENDIX 48
Further letter from the Chairman, Medicines
and Healthcare Products Regulatory Agency to the Clerk of the
Committee (PI 124B)
| 
